NewsBenzinga문레이크 이뮤노테라퓨틱스, 화농성 한선염 치료용 나노바디 소네로키맙에 대한 생물의약품 허가 신청서를 FDA에 제출 문레이크 이뮤노테라퓨틱스, 화농성 한선염 치료용 나노바디 소네로키맙에 대한 생물의약품 허가 신청서를 FDA에 제출 Benzinga 2026.09.30 20:19 (GMT+0) Open on Benzinga Other news Arthur Hayes: Bullish on ETH, ZEC, NEAR and VVV, Has Built Small- and Mid-Sized Positions Huang's Nvidia Return Odds Rebound to 11% on Kalshi Hackers Spread Crypto-Stealing Trojan via Fake GTA 6 PC Download Links Invesco's Stablecoin Reserve Fund Goes Live on Ethereum 7 Major US Banks Disclose XRP ETF Holdings in SEC Filings, Totaling About $29.4M Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading
Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading